NCT07472647 2026-03-16
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Phase 1/2 Not yet recruiting
Clinical Trials
11 trialsNCT07464327 2026-03-11
A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Hansoh BioMedical R&D Company
Phase 3 Not yet recruiting
NCT07459751 2026-03-10
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2/3 Not yet recruiting
NCT07442565 2026-03-04
SYNSTAR03
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT07416994 2026-02-18
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Not yet recruiting
NCT07361484 2026-01-23
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
BeyondSpring Pharmaceuticals Inc.
Phase 3 Not yet recruiting
NCT07242274 2025-11-21
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
Jemincare
Phase 3 Not yet recruiting
NCT06775483 2025-01-15
Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Not yet recruiting
NCT06319313 2024-03-20
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc.
Phase 2/3 Not yet recruiting
NCT05910034 2023-06-18
Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC
Fudan University
Phase 2 Not yet recruiting
NCT04772287 2021-02-26
Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)
Shanghai Pulmonary Hospital, Shanghai, China
Phase 3 Not yet recruiting